The Australian Parkinson's Genetics Study: Insights from A Nationwide Cohort of Nearly 12,000 Australians Living with Parkinson's Disease

Fangyuan Cao[1,2], Kerrie McAloney[1], Natalia S. Ogonowski[1,2], Luis M. García-Marín[1,2], Santiago Díaz-Torres[1,2], Victor Flores-Ocampo[1,2], Zuriel Ceja[1,2], Freddy Chafota[1], Richard Parker[1], Mary Ferguson[1], Rebekah A. Cicero[1], Susan E. List-Armitage[1], Vicki Miller[3], Clyde Campbell[3], Carolyn M. Sue[4,5], Kishore R. Kumar[5,6,7,8], George D. Mellick[9], Nicholas G. Martin[1] and Miguel E. Rentería[1,2,10,*]

1. Brain and Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
2. Faculty of Medicine, Health and Behavioural Medicine, The University of Queensland, Brisbane, QLD, Australia
3. Shake It Up Australia Foundation, Sydney, NSW, Australia
4. Neuroscience Research Australia, Randwick, NSW, Australia
5. Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
6. Department of Neurology and Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, NSW, Australia
7. Sydney Medical School, University of Sydney, Sydney, NSW, Australia
8. Translational Neurogenomics Group, Genomics and Inherited Disease Program, Garvan Institute of Medical Research, Sydney, NSW, Australia
9. Griffith Institute for Biomedicine and Glycomics, Griffith University, Brisbane, QLD 4111, Australia.
10. School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.

*Correspondence: miguel.renteria@qimrb.edu.au

Abstract

Background: Parkinson's disease (PD) is a complex neurodegenerative condition with a heterogeneous clinical presentation and multifactorial aetiology involving genetic, environmental, and lifestyle factors. The Australian Parkinson's Genetics Study (APGS) is an ongoing nationwide, population-based initiative established to advance understanding of the determinants and progression of PD.

Methods: We present a cross-sectional characterisation of 11,986 participants with self-reported PD recruited across Australia through a combination of assisted mailouts, media outreach, and digital engagement. Participants complete comprehensive questionnaires capturing sociodemographic, clinical, environmental, lifestyle, and behavioural data, and provide saliva samples for genetic analysis. A control cohort is currently being recruited and is therefore not reported here.

Results: The cohort is 63% male, with a mean age of 71 years and symptom onset at 64 years. Most participants report being diagnosed by a neurologist (79%), and 25% have a family history of PD. Non-motor symptoms such as depression, anxiety, and sleep disturbances are common, and sex-based differences were observed across clinical features, comorbidities, environmental exposures, and impulsive-compulsive behaviours. Previously reported risk factors were notable in the APGS PD cohort, including pesticide exposure (36%), traumatic brain injury (16%), and employment in high-risk industries (33%). COVID-19 vaccination uptake was near-universal (99%), and most infections were mild.

Conclusions: APGS is the largest PD cohort in Australia and represents a rich resource for investigating the sociodemographic, genetic, and environmental underpinnings of PD. Its comprehensive design and ongoing expansion—including digital phenotyping and genomic profiling—position it as a transformative platform to inform risk prediction, biomarker discovery, and therapeutic development for PD.

Introduction

Parkinson's disease (PD) is a complex, multifactorial neurodegenerative disorder and a major global health priority. As the second most prevalent and fastest-growing neurological condition, PD affects more than 10 million people worldwide, a figure projected to rise further as the global population ages.[1,2] In Australia, over 150,000 people are living with PD, with approximately 50 new diagnoses made each day.[3] The economic impact of PD is substantial, with estimated annual costs reaching AUD 10 billion in 2015,[4] placing considerable pressure on individuals, families, the healthcare system, and society as a whole.

PD is primarily recognised as a movement disorder, characterised by the intracellular accumulation of α-synuclein and progressive loss of dopaminergic neurons in the substantia nigra.[1] Despite growing recognition of PD as a multisystem disorder, clinical practice remains largely centred on motor symptoms, often overlooking non-motor features that may offer opportunities for early detection and intervention. Alongside the hallmark motor signs (e.g., slowness of movement or bradykinesia, rigidity, and tremor), non-motor symptoms such as reduced sense of smell, autonomic disturbances (e.g., constipation, urinary and sexual dysfunction, excessive sweating, and orthostatic hypotension), sleep difficulties, mood and anxiety disorders, cognitive changes, speech and language impairments, and chronic pain also develop along the disease trajectory.[1,5-7] Importantly, many of these symptoms are not only prevalent but may also precede motor symptoms or a formal diagnosis by years or even decades, highlighting their potential as early indicators of disease onset and progression.[6,8,9]

Ongoing efforts to better understand and address PD have led to notable progress, with 136 clinical trials active as of January 2024.[10] Despite this momentum, however, relatively few have progressed to Phase 3, particularly those targeting disease-modification.[10] Current treatment strategies, including levodopa and deep brain stimulation, have improved symptom control but are associated with complications over time,[1,11] and no existing therapy can halt or reverse the neurodegenerative processes. Advancing the development of effective treatments requires deeper insight into the causes and biological pathways involved in PD. While advancing age, especially beyond 60 years, remains the strongest risk factor,[11-13] other factors such as male sex, history of head trauma, high alcohol consumption, rural residence, farming-related occupations, and exposure to pesticides, heavy metals, and environmental pollutants have also been linked to increased PD risk,[11,12,14] though findings have not always been consistent.

Genetic factors also play a crucial role in the pathogenesis of PD, with twin heritability estimates around 34%.[15,16] While most cases are considered complex, shaped by multiple

common genetic variants of small effect in combination with environmental exposures, approximately 10–15% of cases are associated with rare, highly penetrant monogenic variants.[14,17] To date, more than 20 genes have been implicated in monogenic forms of PD, including *SNCA*, *LRRK2*, *PRKN*, *PINK1*, *GBA1*, and *PARK7*.[18,19] These genes are linked to idiopathic and early-onset PD as well as other Parkinsonian syndromes. Notably, variants in *SNCA*, *LRRK2*, and *GBA* also contribute to sporadic PD risk.[17,20] Genome-wide association studies (GWAS) have expanded our understanding of the genetic architecture of PD, identifying up to 134 independent risk variants.[21,22] However, these loci explain only a small fraction of the observed heritability,[17,21] leaving a substantial proportion of genetic risk unexplained. Capturing this "missing heritability" will require a near threefold increase in GWAS sample sizes.[19]

The Global Parkinson's Genetics Program (GP2) is a major international initiative that aims to uncover the genetic architecture of PD by harmonising data from diverse populations around the world.[23] Within this framework, the Australian Parkinson's Genetics Study (APGS) is the largest nationwide study for PD in Australia and represents a transformative effort to accelerate discovery in the field. Its overarching goal is to expand sample collection and genotyping to identify both genetic and environmental risk factors, thereby enhancing our understanding of PD, informing improved diagnostic and screening strategies, and ultimately contributing to prevention. Having reached the milestone of enrolling over 10,000 individuals diagnosed with PD, this manuscript presents a comprehensive characterisation of the APGS cohort so far. We describe key sociodemographic, clinical and lifestyle features of participants and explore sex-specific differences across these domains.

Methods

Study overview

The APGS is a large-scale research initiative led by the Queensland Institute of Medical Research (QIMR Berghofer) in Brisbane, Australia. The study seeks to characterise the phenotypic, genetic, and environmental diversity associated with PD, with the goal of identifying risk and protective factors that influence disease onset and progression. To achieve this, APGS aims to recruit and follow a nationwide cohort of 10,000 individuals diagnosed with PD and 10,000 unaffected controls.

This cohort also contributes to the Global Parkinson's Genetics Program (GP2), an international collaboration focused on accelerating therapeutic discovery and development in PD by advancing genetic research across ancestrally and geographically diverse populations.

As of July 2024, APGS has successfully reached its target of enrolling 10,000 participants diagnosed with PD. This manuscript describes the recruitment process to date and presents a cross-sectional analysis of baseline data from the PD cohort. The analysis includes sociodemographic, clinical, lifestyle and environmental characteristics, and explores sex-based differences across these domains.

The APGS protocol was approved by the Human Research Ethics Committee of the QIMR Berghofer Medical Research Institute (P3711). All participants provided informed consent, including agreement to be recontacted for future related research, with voluntary participation clearly communicated. Data are securely managed in accordance with the Commonwealth Privacy Act (1988) and the National Health and Medical Research Council (NHMRC) Guidelines.

Recruitment and inclusion criteria

Recruitment strategies are described in detail in a previous publication outlining the pilot phase of the study.[24] Briefly, APGS uses a time- and cost-effective recruitment approach by collaborating with *Services Australia* (previously known as the Australian Government Department of Human Services) to conduct an assisted mailout. This method enables the study to reach a random sample of individuals across Australia who have been prescribed PD-related medications listed under the Pharmaceutical Benefits Scheme (PBS).

Services Australia is a government agency that delivers a range of social and health-related services to Australian citizens and permanent residents. Among its responsibilities, the agency administers the PBS, a national program that subsidises prescription medicines for eligible Australians (Further details and a full list of subsidised medicines can be found at https://www.pbs.gov.au/pbs/). It maintains prescription records for the previous five years and, with appropriate ethics approval, supports health-related research by coordinating mailouts on behalf of research organisations.

Importantly, the recipient's personal data remain confidential throughout this process: *Services Australia* does not share any identifiable information with researchers, ensuring participant privacy and data security at all times.

In 2020, our team conducted a pilot study—described in detail elsewhere[24]— in which over 1,500 individuals were recruited and provided a saliva sample for DNA extraction and characterisation. Building on this initial success, and with the support of the Global Parkinson's Genetics Program (GP2), as well as funding from the Shake It Up Australia Foundation and the Michael J. Fox Foundation, we launched full-scale nationwide

recruitment in April 2022. The rollout began during *Parkinson's Awareness Month*, accompanied by a national communications campaign and public appeal. In September 2022, 100,000 invitation letters were distributed by *Services Australia* to individuals who met the following criteria: Australian citizens or permanent residents, aged 40 to 75 years, and had at least one PBS claim within the past two years for medications commonly used to manage PD symptoms. (See Supplementary Table 1 for a list of included medications and their corresponding PBS codes.) Subsequent recruitment waves followed: an additional 60,000 letters were distributed in July 2023, and a further 26,000 letters in June 2024.

Data collection

The invitation letters sent through mail directed potential participants to the APGS study website, where they could learn more about the project and sign up to participate. Informed consent was obtained electronically via the website prior to questionnaire completion and saliva collection.

After providing informed consent, participants were invited to submit their contact details and complete a questionnaire, either online via the Qualtrics Platform (https://www.qualtrics.com) or, if preferred, through a paper-based version sent out by mail. More information about APGS is available at the study website: https://www.qimrb.edu.au/studies/apgs.

The questionnaire was designed to capture comprehensive information across a range of domains, including sociodemographic characteristics, clinical features, lifestyle factors, environmental exposures, and medical and behavioural history. It is organised into several sections, as summarised in **Table 1**.

Upon completion of the questionnaire, participants who met the eligibility criteria were invited to provide a saliva sample for genetic analysis. Those who consented to participate in the genetic component of the study were contacted by the research team to confirm their details and mailing address. A saliva collection kit (Isohelix or Thermo Fisher), along with detailed instructions for sample collection and a prepaid return envelope, was then dispatched to the participant's nominated address. Participants were asked to self-collect their saliva sample and return it by traditional post to our research laboratory in Brisbane for processing.

Statistical analyses

Summary statistics were reported as frequencies and percentages for categorical variables and as means and standard deviations (SD) for continuous variables, along with the number of

participants available for each variable. Medians and interquartile ranges (IQR) were also reported for continuous variables to provide a more thorough view of the data distribution.

Independent t-tests and chi-square tests were performed to compare males and females for continuous and categorical variables, respectively. In cases where continuous data deviated from normality, the non-parametric Mann-Whitney U test was also used, with normality assessed by visualising histograms and quantile-quantile (Q-Q) plots. Given the large sample size of our cohort, the p-values from both parametric (independent t-tests) and non-parametric tests were nearly identical, and thus, only p-values from the parametric tests are reported.

Statistical significance was set at the alpha level of 0.05. All statistical analyses and data visualisations were performed using Python 3.12.5, utilising the *Pandas*, *NumPy*, *Scipy* and *Matplotlib* libraries.

Results

Sample accrual

Recruitment occurred in distinct phases between May 2020 and July 2024 (**Figure 1A**), and the geographic composition of participants by Australian state and territory (**Figure 1B**) reflected the national population distribution. The initial *pilot* mail-out in mid-2020 resulted in a sharp rise in participation, with over 1,000 questionnaires completed in June 2020 alone. Following this, monthly completions declined but remained steady at low levels until a second peak in April 2021, driven by a national media campaign.

The first large-scale national mail-out (100,000 letters), launched in September 2022, generated the most substantial response, with a peak of over 1,200 surveys completed in October 2022. After this wave, participation tapered off before rising again in response to a second mail-out in July 2023 (60,000 letters), which produced a moderate but sustained increase in completions through late 2023. A final recruitment push in June 2024 (26,000 letters) led to another uptake in survey responses.

These successive recruitment waves collectively enabled the study to reach its target of 10,000 participants diagnosed with Parkinson's disease. The pattern of monthly completions reflects the effectiveness of targeted outreach strategies and confirms the feasibility of large-scale, remote participant engagement using government-assisted mail-outs and media support.

Demographics

Of the 11,986 participants with PD recruited into the study by 31 July 2024, approximately 95% completed over 90% of the questionnaire, and 89% responded via the online platform (**Table 2**). The cohort was 63% male, with an average age of 71 ± 9 years and a mean body mass index (BMI) of 27 ± 5 kg/m². The sample was predominantly of European ancestry (93%), non-religious (63%), married or in a de facto relationship (78%), and had children (89%), with 45% of those participants having two children or more. Most participants were right-handed (87%) and just over half identified as "morning people" (52%). A total of 74% had completed at least high school education, and 14% reported speaking more than one language.

Males were slightly older than females on average (71 vs. 70 years) and more likely to be married or in a de facto relationship (85% vs. 67%), left-handed (11% vs. 9%), or ambidextrous (4% vs. 3%). Males also had slightly higher education attainment, with 13% holding a postgraduate degree compared to 10% of females. In contrast, females were more likely to be divorced or separated (13% vs. 7%) or widowed (15% vs. 4%), to identify as religious or spiritual (46% vs. 32%), to be vegetarian (4% vs. 2%), and to describe themselves as "evening people" (27% vs. 22%; $p < 0.001$ for all comparisons).

Parkinson's disease-related outcomes

Most participants (79%) reported being diagnosed by a neurologist, with a mean age of 64 ± 11 years at symptom onset and 67 ± 10 years at diagnosis (**Table 3**). Unilateral symptom onset was reported by 78%, with 53% noting the right side as initially affected. The most common initial symptom was tremor or shaking (52%), followed by bradykinesia (13%) and rigidity or stiffness (7%). Over half of the participants also reported experiencing concurrent symptoms such as hyposmia, orthostatic light-headedness, memory changes, and pain. Notably, 97% of participants reported sleep disturbances, including difficulty falling or staying asleep at night, daytime sleepiness, vivid or disturbing dreams, dream enactment, or restless legs. In terms of treatment, 94% had been prescribed levodopa, and 7% had undergone neurosurgical intervention, primarily deep brain stimulation.

Females had a slightly earlier average symptom onset (63 vs. 64 years) and were younger at both diagnosis and initiation of levodopa therapy. A greater proportion of females experienced unilateral onset (81% vs. 75%) and left-sided onset (48% vs. 46%). Rigidity or stiffness was more common at onset among females (8% vs. 7%), while bradykinesia was more frequently reported by males (14% vs. 11%). Additionally, females were more likely to experience falls (46% vs. 41%), sleep disturbances (97% vs. 96%), and pain (65% vs. 57%),

whereas memory changes were more frequently reported by males (68% vs. 62%; $p = 0.034$ to <0.001 across all comparisons).

Family history

The most commonly reported familial condition was PD, observed in 25% (2,988) of participants (**Figure 2A**). Among participants with a positive family history of PD, 37% (1,108) reported having affected parents, followed by 21% (630) with affected siblings and 18% (541) with affected grandparents (**Figure 2B**). The majority (78%) reported only one affected relative, while a smaller proportion had two or more. Notably, eight participants reported having five or more relatives with PD (**Figure 2C**).

Dementia of unknown or unspecified type was the second most common family history condition (21%), followed by Alzheimer's disease (14%) and tremor (6%). Additionally, 21% reported no family history for any of the assessed conditions.

Across all assessed conditions, a positive family history was more frequently reported by female participants. Statistically significant sex differences were observed for several disorders. PD was reported by 28% of females compared to 23% of males. Similarly, reports of vascular dementia (4% vs. 2%), epilepsy (4% vs. 3%), Alzheimer’s disease (15% vs. 14%), essential tremor (5% vs. 4%), dementia with Lewy bodies (2.2% vs. 1.6%), and dystonia (0.8% vs. 0.5%; $p = 0.032$ to < 0.001) were all more common among female participants than their male counterparts. These findings suggest potential sex-specific patterns in the familial aggregation of neurological conditions within the cohort.

Lifestyle, events and environmental risk factors

Regular consumption of caffeinated beverages was common among participants, with 76% reporting coffee intake and 70% reporting tea intake, each averaging approximately two cups per day (**Table 4**). Alcohol use was also prevalent: 69% of participants reported current alcohol consumption, and 31% indicated a history of heavy alcohol use. In contrast, regular well water consumption was only reported by 5% of the cohort. While active smoking was less widespread overall, second-hand smoke exposure was relatively common. Thirty-eight percent of participants had a history of smoking, with 94% of them identifying as former smokers. Additionally, 63% reported exposure to second-hand smoke at home, and 25% experienced exposure in the workplace.

A history of major head injury was reported by 16% of participants, with 62% of these cases involving a loss of consciousness. Pesticide or herbicide exposure was reported by 36%, and

25% had lived or worked on a farm for more than one year. Furthermore, 33% had worked in high-risk industries such as metal melting, galvanisation, milling, petrochemicals, agriculture, wood processing, textiles, or industrial painting. A history of heavy metal poisoning was reported by 1% of the sample.

Statistically significant sex differences emerged across several lifestyle and environmental variables ($p \leq 0.001$ across all findings). Males were more likely than females to report consumption of coffee (78% vs. 71%), caffeinated beverages (24% vs. 16%), and alcohol (75% vs. 60%), both in terms of prevalence and quantity. Well water consumption was also more common among males (6% vs. 4%). Conversely, females reported higher average tea consumption (74% vs. 68%). A history of heavy alcohol use was reported by more than twice as many males as females (39% vs. 16%). Similarly, a greater proportion of males had ever smoked (42% vs. 32%), although the proportions of current and former smokers were comparable across sexes.

Major head injury was more frequently reported by males (18% vs. 13%), as was exposure to pesticides or herbicides (42% vs. 28%) and employment in high-risk occupations (43% vs. 16%). These findings highlight notable sex-based differences in environmental and occupational exposures within the cohort.

Medical history

Participants reported a wide range of co-occurring medical conditions. Commonly reported neurological and sleep-related disorders included restless legs syndrome (20%), migraine (19%), sleep apnoea (15%), essential tremor (12%), insomnia (11%), and rapid eye movement sleep behaviour disorder (RBD) (10%) (**Figure 3**).

Several mental health conditions were also prevalent, with depression affecting 28% of participants and anxiety reported by 19%. In addition, a number of non-neurological comorbidities were frequently observed, including allergies (49%), back problems (48%), cataracts (44%), and vision conditions (16%–34%), depending on the specific diagnosis. Hypertension (41%), constipation (40%), high cholesterol (37%), cancer (17%–36%), hearing loss (31%), osteoarthritis (29%), cold sores (28%), and frequent acid reflux (27%) were also commonly reported.

Clear sex-based differences in medical history were observed across multiple domains ($p = 0.036$ to < 0.001 across all findings). Females reported higher rates of pain-related conditions, such as migraine (27% vs. 14%) and osteoarthritis (38% vs. 23%), as well as thyroid disorders (2–9% in females vs. 1–2% in males, depending on the type). Mental health

conditions were also more common in females, with depression reported in 33% of females vs. 26% of males, and anxiety in 23% vs. 17%, respectively.

In contrast, males had a higher prevalence of cardiovascular and metabolic conditions, including hypertension (42% vs. 39%), heart disease (17% vs. 8%), and diabetes (15% vs. 11%). Males also more frequently reported cognitive impairments, such as Parkinson's disease dementia (7% vs. 4%) and mild cognitive impairment (MCI) (9% vs. 5%), along with sleep disorders including sleep apnoea (19% vs. 9%) and RBD (12% vs. 7%). Additionally, cancer diagnoses were more frequently reported by males, with prevalence ranging from 19% to 39% in males compared to 13% to 31% in females, depending on cancer type.

Impulsivity and compulsivity behaviours

Overall, most participants exhibited no or only mild levels of impulsive or compulsive behaviours. Behaviours such as compulsive performance of repetitive, mechanical tasks (punding) or hobbies (hobbyism) and use of PD medication, along with compulsive eating, shopping, and sexual behaviours, were reported more frequently than gambling (**Figure 4**).

When asked about difficulties controlling thoughts related to these behaviours, 18% of participants responded "often" and 7% "very often" (**Figure 4A**). In comparison, fewer than 10% reported experiencing excessive urges that caused distress "often" or "very often" (**Figure 4B**), and less than 4% reported having difficulty controlling the behaviours themselves at the same frequency (**Figure 4C**). Engaging in actions to sustain these behaviours, such as hiding, lying, accumulating debt, or engaging in illegal activity, was rare; fewer than 7% reported doing so "sometimes" (**Figure 4D**).

Sex-based differences were evident in the manifestation of impulsivity and compulsivity across all behavioural domains. Males generally reported higher levels of overt impulsivity, particularly in relation to sexual behaviour, punding, hobbyism, and gambling ($p \leq 0.003$ across all findings). For example, in the domain of compulsive sexual behaviour, substantially more males than females reported experiencing these difficulties "sometimes," "often," or "very often." Specifically, 56% of males vs. 20% of females reported difficulty suppressing intrusive thoughts, 31% vs. 7% experienced excessive urges, 16% vs. 3% struggled with controlling the behaviour, and 9% vs. 1% admitted to engaging in actions to sustain the behaviour.

COVID-19

The cohort demonstrated a very high COVID-19 vaccination uptake, with 99% of participants reporting at least one dose, and 74% receiving four or more doses (**Table 5**). Forty-four percent had contracted COVID-19, and in the majority of these cases (86%), infection occurred after vaccination. On average, participants reported one COVID-19 infection. Most infections were classified as mild (56%), while 7% reported severe symptoms, and 4% required hospitalisation.

Females were more likely than males to report moderate to severe symptoms following COVID-19 infection, with 41% of females affected compared to 37% of males (p = 0.02 to 0.037). No other significant sex-based differences were observed across COVID–19–related variables.

Discussion

The APGS represents the largest Australian cohort dedicated to PD research. By employing a combination of innovative and large-scale recruitment strategies, the study aims to uncover the genetic and environmental factors influencing disease onset and progression, deepen understanding of underlying aetiological mechanisms, and ultimately inform the identification of novel therapeutic targets. In this paper, we provide a comprehensive characterisation of individuals with PD enrolled in APGS (N=11,986), covering a wide array of sociodemographic, lifestyle, environmental, clinical, family history, and COVID-19-related factors.

In our cohort, the average age was 71 years, with a mean age of 64 years at symptom onset and 67 years at diagnosis. These values are consistent with earlier reports indicating a sharp rise in PD incidence beyond the age 60.[13,14,25] A meta-analysis of 47 studies further corroborates this trend, showing a dramatic increase in global incidence, from approximately 41 per 100,000 in the 40–49 age group, to 428 per 100,000 in those aged 60–69 and 1,903 per 100,000 in those over 80 years of age.[13] Aging is widely recognised as a strong PD risk factor. While advancing age alone does not fully account for disease onset, age-related declines in dopamine metabolism, protein degradation, and mitochondrial function heighten the vulnerability of *substantia nigra* neurons to further genetic and environmental insults.[20,26]

Male sex is another well-established risk factor for PD. Numerous studies across different populations have consistently reported that PD prevalence and incidence are approximately twice as high in men compared to women.[14,25,27] This pattern is mirrored in the APGS cohort, in which 63% of participants are male. The prevailing hypothesis posits that estrogen may exert neuroprotective effects on dopaminergic neurons, potentially through modulation of

nigrostriatal dopamine synthesis, release, metabolism, receptor binding, and anti-inflammatory pathways.[28-30] However, it is also plausible that sex-specific environmental exposures[31] and genetic mechanisms[32,33] contribute to the higher prevalence of PD in males. Our findings indicate that male participants had higher levels of education, greater alcohol consumption, higher smoking prevalence, and greater exposure to pesticides and high-risk occupations compared to females. Further research is needed to disentangle the independent and interacting contributions of sex, environment, and genetics, which may help inform the development of sex-tailored treatment strategies.

Sex differences in the clinical presentation of PD have also been widely documented. In our cohort, tremor or shaking was the most common initial symptom; however, female participants more frequently reported rigidity or joint stiffness, whereas bradykinesia was more commonly reported in males. Previous studies suggest that motor symptoms may emerge later in females than in males,[34,35] possibly due to sex differences in striatal dopamine receptor expression, specifically, a higher ratio of dopamine receptor D1 (facilitatory) to D2 (inhibitory) in the striatum in women.[36] Our results also revealed that females more frequently experienced falls, sleep disturbances (e.g., trouble falling asleep), and pain, while males more commonly reported cognitive changes. These findings are broadly consistent with existing literature indicating that females with PD tend to have more psychiatric symptoms, pain, gastrointestinal and cardiovascular autonomic dysfunction, and postural instability, leading to an increased risk of falls. In contrast, males appear more prone to earlier and more rapid cognitive decline, as well as sleep behaviour disorders, including RBD.[34,35,37-40]

It has been proposed that distinct or differently operating pathogenic pathways in males and females, particularly involving the dopaminergic system, neuroinflammation, and oxidative stress, may underlie these sex differences in PD.[34,35,40] However, the mechanistic remains limited, and additional research is needed to better understand how biological sex interacts with disease processes and clinical progression.

PD is characterised by a complex genetic architecture. A positive family history is associated with a two- to threefold increased risk of developing PD in both familial and sporadic forms.[41-43] Case-control studies have shown that 15-25% of PD cases report a family history, with 10-20% involving a first-degree relative.[41,44-47] In our study, one in four APGS participants reported a family history of PD, reinforcing the well-established association between genetic susceptibility and PD risk. The high prevalence of affected first-degree

relatives, particularly parents and siblings, suggests the involvement of both inherited genetic variants and/or shared environmental exposures.

This association appears more pronounced in males and individuals of European ancestry compared to females and individuals of other ancestries.[48] While most participants reported only one affected relative, a subset reported multiple affected family members, including rare instances of five or more cases per family. Such familial clustering may reflect the presence of rare, highly penetrant variants.[15,49]

Beyond PD, many APGS participants reported family histories of other neurodegenerative diseases, including dementia, Alzheimer's disease, and tremor, further supporting evidence of shared genetic risk and overlapping pathogenic pathways.[50,51] Interestingly, female participants more frequently reported a family history of these conditions, a pattern that may arise from a combination of biological and sociocultural factors. For instance, women may be more engaged in family health matters and thus more likely to recall and report familial conditions.[52] Alternatively, sex-specific differences in disease expression, genetic susceptibility, or familial risk transmission, as observed in other neurodegenerative diseases, may play a role.[34,35,53] These findings highlight the importance of detailed family history assessments in PD research to enhance risk stratification and understanding of heritable disease architecture.

Environmental and lifestyle factors also contribute significantly to PD risk. For example, exposure to toxicants such as pesticides, solvents, heavy metals, and industrial pollutants has long been recognised as a PD risk factor, with effects of specific pesticide compounds replicated in animal models.[12,54,55] Furthermore, traumatic head injury has been linked to both a higher risk and earlier onset of PD[56] as well as other neurodegenerative disorders, including Alzheimer's disease and dementia.[57] In contrast, tobacco use, caffeine consumption, and certain dietary factors, such as increased intake of fruits, vegetables, and whole grains, have been associated with a lower the risk of PD.[12,20,54] Consistent with this literature, a substantial proportion of APGS participants reported pesticide exposure and potential occupational contact with hazardous substances, ranging from one-quarter to one-third of the cohort. We also observed a notably high prevalence of major head injury relative to the general Australian population, where the estimated rate is 1 in 45, with three-quarters of cases occurring in individuals under the age of 65.[58] In contrast, current smoking rates in our cohort were lower than national averages, with 6% of APGS participants identifying as current smokers, compared to 11.1% of adults in the 2022-23 National Drug Strategy Household Survey.[59]

While these findings broadly align with prior studies, the biological mechanisms through which lifestyle factors influence PD susceptibility remain incompletely understood. Significant variability across studies persists. For example, although smoking has been inversely associated with PD risk,[12,20] some research indicates that smokers may experience earlier disease onset,[23,61] accelerated cognitive decline,[24,60] more frequent symptoms such as drooling, dysphagia and mood disturbances,[61] and increased mortality.[62] These contrasting findings underscore the complex and multifactorial nature of PD risk and progression, and the need for further prospective, mechanistic research.

PD is associated with a range of comorbidities, some of which may be involved in its pathogenesis and progression, while others could represent prodromal signs. In the APGS cohort, depression, restless legs syndrome, anxiety, migraine, sleep apnoea, insomnia, and RBD were reported in 10-28% of participants. Among these, sleep disorders (e.g., restless leg syndrome, sleep apnoea, and RBD) are common in PD, due to neurodegeneration in sleep-regulating brain regions[63] and are often associated with subsequent disease development,[56] typically emerging years or even decades before diagnosis.[56,64] These disturbances can lead to daytime fatigue, mood symptoms, and physical issues such as muscle tension, palpitations, and headaches,[63] many of which were common in our sample.

Psychiatric comorbidities, particularly depression and anxiety, affect up to 89% of people with PD[65-67] and are associated with worse prognosis and greater disability.[65,68,69] The exact nature of these associations remains debated. Hypotheses include the possibility that such symptoms are intrinsic to the disease process,[56,70,71] reflect shared pathophysiological pathways or genetic predisposition,[72,73] or represent a psychological response to the life changes brought about by the diagnosis.[71]

We also identified several other frequently reported comorbidities in the cohort, including constipation, frequent acid reflux, vision and eye conditions, hypertension, cancers, and hearing loss. These conditions have been widely documented in the literature and may precede the onset of PD in some individuals.[56,69,74] The growing evidence of such comorbidities further underscores the clinical complexity of PD, and a better understanding of the molecular mechanisms linking these conditions may contribute to the identification of novel biomarkers and therapeutic targets.

Impulse control disorder (ICD) is another important comorbidity, affecting up to 20% of people with PD[75-77] and having a significant impact on quality of life and disease burden. ICD is strongly associated with dopaminergic therapies, especially dopamine agonists and higher doses of dopamine replacement therapy,[76,77] although a 17.5% prevalence has been observed

even before treatment initiation.[75] Other known risk factors include early onset PD, a prior history of ICD, substance use, and specific personality traits.[75-77] Gender differences in ICD presentation are well established: males are more likely to exhibit hypersexuality and higher impulsivity, while females more often show compulsive shopping and eating behaviours.[35,75,76]

In the APGS, most participants reported mild to moderate impulsivity. Up to 18% responded "often" and 7% "very often" when asked about difficulties controlling thoughts related to behaviours such as punding, hobbyism, compulsive PD medication use, eating, shopping, sexual activity, and gambling. However, fewer participants reported difficulty controlling the behaviours themselves. Greater impulsivity was observed among males, particularly for sexual behaviour, followed by punding, hobbyism, and gambling. In contrast, the same trend was not observed for compulsive shopping and eating among females. This may reflect gender differences in societal expectations, emotional coping strategies, or reporting tendencies. Another possible explanation lies in neurobiological sex differences, such as stronger mesocorticolimbic reward system connectivity in males.[75,78]

We also examined variables related to COVID-19, as the APGS recruitment period coincided with the global pandemic. People with PD were prioritised for vaccination due to their increased vulnerability to complications.[79,80] In our cohort, 99% of participants were vaccinated, and 74% received four or more doses. These results align with national vaccination coverage in Australia during the study recruitment[81] and reflect high compliance among this group, who were among the earliest recipients of vaccines during the national rollout.[82] Moreover, 44% of participants had contracted COVID-19, with most cases classified as mild and a small proportion requiring hospitalisation, supporting earlier findings that vaccination reduces disease severity, particularly in at-risk populations.[83] Interestingly, females reported more severe COVID-19 symptoms than males, which may be explained by sex-based differences in immune responses[84] or gender-related disparities in comorbidities, healthcare access, or social determinants of health.

The APGS has several important strengths. First, through a combination of innovative, cost-effective recruitment strategies, the study has successfully established the largest nationwide population-based PD cohort in Australia and one of the largest globally. Second, the project collected an exceptionally rich dataset, encompassing sociodemographic information, lifestyle behaviours, occupational and environmental exposures, and detailed clinical domains, including family and medical histories, impulsive and compulsive behaviours, and COVID–19–related variables. Third, recruitment is ongoing for both cases and controls, and

the majority of participants have been genotyped, with a subset undergoing whole-genome sequencing from saliva samples. In addition, the APGS platform supports several sub-studies, including MonoPDAus,[85] Cognition and PD, and Speech and Parkinson's, which focus on monogenic forms, as well as cognition- and speech-related aspects of PD. These initiatives further enhance the translational potential of APGS as a platform for future discovery, intervention, and personalised medicine.

Limitations

This study has several limitations. First, the response rate was modest (~10,000 participants from 186,000 invitations), introducing potential self-selection bias. Second, the cohort is predominantly of European ancestry, limiting the generalisability of findings to more diverse populations. Third, the remote design, while enabling national reach, may affect the precision of clinical phenotyping, particularly for symptom onset and severity, and may introduce self-report bias. Fourth, this is a descriptive analysis without an age- and sex-matched control group; control recruitment and genotyping are ongoing. Future expansions will incorporate digital biomarkers from smartphones and wearables, alongside electronic patient-reported outcomes, to capture longitudinal, objective, and patient-centred data.

Conclusion

This study presents a comprehensive characterisation of individuals with PD enrolled in the Australian Parkinson's Genetics Study (APGS). As the largest PD cohort established in Australia, APGS is uniquely positioned to advance understanding of the sociodemographic, genetic, and environmental factors influencing disease susceptibility, presentation, and progression. By contributing to national and international research efforts, the study will support the discovery of novel therapeutic targets and accelerate the development of strategies aimed at preventing, slowing, or modifying the course of PD.

Acknowledgments

We are deeply grateful to all the participants of the Australian Parkinson's Genetics Study (APGS) whose invaluable contributions and commitment made this research possible. We would like to thank Michael Katz and Richard Balanson for their valuable input and contributions in setting up the study. We thank the Health Data Analysis and Strategy Branch team at Services Australia for their kind assistance and facilitating the mail outs. APGS is supported by the Shake It Up Australia Foundation and the Michael J. Fox Foundation for

Parkinson's Research (MJFF-021952). MER thanks the support from the Rebecca L. Cooper Medical Research Foundation (F20231230). KRK is supported by grants from the Medical Research Future Fund, the Lord Mayor's Charitable Fund, and the Ainsworth 4 Foundation (unrelated to the current study).

Author Contributions statement

F.Cao performed all statistical analyses and wrote the first draft of the manuscript. K.M., R.P., M.F., R.A.C., and S.E.L.-A. were responsible for study operations, including participant engagement, saliva sample collection and processing, implementation of the electronic questionnaire, among other tasks. N.S.O., L.M.G.-M., S.D.-T., V.F.-O., Z.C., and F.Chafota contributed to the interpretation of data and provided input on the analysis and manuscript structure. V.M. and C.C. actively contributed to participant recruitment through media engagement and advocacy. C.M.S. and K.R.K. contributed clinical expertise and reviewed the manuscript for accuracy in clinical interpretation. G.D.M. and N.G.M. helped design the study, including the questionnaire, and provided senior scientific guidance. M.E.R. conceived and led the study, coordinated the research team, and oversaw the preparation and revision of the manuscript. All authors critically reviewed the manuscript for intellectual content and approved the final version for submission.

Data availability

The data supporting the findings of this study are not publicly accessible due to participant privacy considerations. However, anonymised datasets can be made available to qualified researchers upon request to the corresponding author. Data sharing will be contingent upon obtaining all necessary ethical approvals and signing an institutional data transfer agreement.

Code availability

Researchers may contact the corresponding author to request access to the code used for data processing and analysis.

References

1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.

2. Statistics Parkinson's Foundation2025 [cited 21 Jan 2025. Available from: https://www.parkinson.org/understanding-parkinsons/statistics.

3. Mellick GD. Ecosystem of Parkinson's in Australia Project Report. PART 2: Systemic Review. Parkinson's Australia; 2024.

4. Statistics Parkinson's Australia [updated 06 May 2024; cited 2024 20 May]. Available from: https://www.parkinsons.org.au/statistics/#:~:text=Young%20Onset%20Parkinson's%20makes%20up,to%20the%20World%20Health%20Organisation.

5. Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study). Movement Disorders. 2015;30(2):229-37.

6. Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. Journal of Neurochemistry. 2016;139(S1):318-24.

7. Ogonowski NS, Chafota F, Cao F, Yin Lim AW, Flores-Ocampo V, Díaz-Torres S, et al. Chronic Pain in Parkinson's Disease: Prevalence, Sex Differences, Regional Anatomy, and Multiple Comorbidities. medRxiv. 2025:2025.02.09.25321969.

8. Mahlknecht P, Seppi K, Poewe W. The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis. 2015;5(4):681-97.

9. Magee M, Copland D, Vogel AP. Motor speech and non-motor language endophenotypes of Parkinson's disease. Expert Rev Neurother. 2019;19(12):1191-200.

10. McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update. J Parkinsons Dis. 2024;14(5):899-912.

11. Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(8):795-808.

12. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1-12.

13. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson's disease: A systematic review and meta-analysis. Movement Disorders. 2014;29(13):1583-90.

14. de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. The Lancet Neurology. 2006;5(6):525-35.

15. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46(9):989-93.

16. Wirdefeldt K, Gatz M, Reynolds CA, Prescott CA, Pedersen NL. Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol Aging. 2011;32(10):1923.e1-8.

17. Ohnmacht J, May P, Sinkkonen L, Krüger R. Missing heritability in Parkinson's disease: the emerging role of non-coding genetic variation. Journal of Neural Transmission. 2020;127(5):729-48.

18. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature Reviews Disease Primers. 2017;3(1):17013.

19. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19(2):170-8.

20. Pang SY-Y, Ho PW-L, Liu H-F, Leung C-T, Li L, Chang EES, et al. The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease. Translational Neurodegeneration. 2019;8(1):23.

21. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet Neurology. 2019;18(12):1091-102.

22. The Global Parkinson's Genetics Program (GP2), Hampton L. Leonard. Novel Parkinson's Disease Genetic Risk Factors Within and Across European Populations. medRxiv. 2025:2025.03.14.24319455.

23. GP2: The Global Parkinson's Genetics Program. Mov Disord. 2021;36(4):842-51.

24. Bivol S, Mellick GD, Gratten J, Parker R, Mulcahy A, Mosley PE, et al. Australian Parkinson's Genetics Study (APGS): pilot (n=1532). BMJ Open. 2022;12(2):e052032.

25. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. American Journal of Epidemiology. 2003;157(11):1015-22.

26. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14(100):19-30.

27. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in

men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55(9):1358-63.

28. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism & Related Disorders. 2002;8(5):289-95.

29. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819-24.

30. Lee YH, Cha J, Chung SJ, Yoo HS, Sohn YH, Ye BS, Lee PH. Beneficial effect of estrogen on nigrostriatal dopaminergic neurons in drug-naïve postmenopausal Parkinson’s disease. Scientific Reports. 2019;9(1):10531.

31. Schaffner SL, Tosefsky KN, Inskter AM, Appel-Cresswell S, Schulze-Hentrich JM. Sex and gender differences in the molecular etiology of Parkinson’s disease: considerations for study design and data analysis. Biology of Sex Differences. 2025;16(1):7.

32. López-Cerdán A, Andreu Z, Hidalgo MR, Grillo-Risco R, Català-Senent JF, Soler-Sáez I, et al. Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies. Biology of Sex Differences. 2022;13(1):68.

33. Tranchevent L-C, Halder R, Glaab E. Systems level analysis of sex-dependent gene expression changes in Parkinson’s disease. npj Parkinson's Disease. 2023;9(1):8.

34. Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference? J Parkinsons Dis. 2019;9(3):501-15.

35. Cattaneo C, Pagonabarraga J. Sex Differences in Parkinson’s Disease: A Narrative Review. Neurology and Therapy. 2025;14(1):57-70.

36. Cullity ER, Madsen HB, Perry CJ, Kim JH. Postnatal developmental trajectory of dopamine receptor 1 and 2 expression in cortical and striatal brain regions. J Comp Neurol. 2019;527(6):1039-55.

37. Reekes TH, Higginson CI, Ledbetter CR, Sathivadivel N, Zweig RM, Disbrow EA. Sex specific cognitive differences in Parkinson disease. npj Parkinson's Disease. 2020;6(1):7.

38. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, Hu MT. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99-105.

39. Iwaki H, Blauwendraat C, Leonard HL, Makarious MB, Kim JJ, Liu G, et al. Differences in the Presentation and Progression of Parkinson's Disease by Sex. Mov Disord. 2021;36(1):106-17.

40. Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord. 2010;25(16):2695-703.

41. Sellbach AN, Boyle RS, Silburn PA, Mellick GD. Parkinson's disease and family history. Parkinsonism & Related Disorders. 2006;12(7):399-409.

42. Rocca WA, McDonnell SK, Strain KJ, Bower JH, Ahlskog JE, Elbaz A, et al. Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Annals of Neurology. 2004;56(4):495-502.

43. Arienti F, Casazza G, Franco G, Lazzeri G, Monfrini E, Di Maio A, et al. Family History in Parkinson's Disease: A National Cross-Sectional Study. Movement Disorders Clinical Practice. 2024;11(11):1434-40.

44. Marder K, Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, et al. Familial aggregation of early- and late-onset Parkinson's disease. Annals of Neurology. 2003;54(4):507-13.

45. Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, Myers RH. Environmental, medical, and family history risk factors for Parkinson's disease: A New England-based case control study. American Journal of Medical Genetics. 1999;88(6):742-9.

46. McCann SJ, LeCouteur DG, Green AC, Brayne C, Johnson AG, Chan D, et al. The Epidemiology of Parkinson’s Disease in an Australian Population. Neuroepidemiology. 1998;17(6):310-7.

47. Uitti RJ, Baba Y, Wszolek ZK, Putzke DJ. Defining the Parkinson's disease phenotype: initial symptoms and baseline characteristics in a clinical cohort. Parkinsonism & Related Disorders. 2005;11(3):139-45.

48. Marder K, Tang M-X, Mejia H, Alfaro B, Cote L, Louis E, et al. Risk of Parkinson's disease among first-degree relatives. Neurology. 1996;47(1):155-60.

49. Klein C, Westenberger A. Genetics of Parkinson’s Disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1).

50. Wainberg M, Andrews SJ, Tripathy SJ. Shared genetic risk loci between Alzheimer’s disease and related dementias, Parkinson’s disease, and amyotrophic lateral sclerosis. Alzheimer's Research & Therapy. 2023;15(1):113.

51. Tarakad A, Jankovic J. Essential Tremor and Parkinson's Disease: Exploring the Relationship. Tremor Other Hyperkinet Mov (N Y). 2018;8:589.

52. Mielke MM, Vemuri P, Rocca WA. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin Epidemiol. 2014;6:37-48.

53. Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, et al. Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's & Dementia. 2018;14(9):1171-83.

54. Tanner CM, Goldman SM, Ross GW, Grate SJ. The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk. Alzheimer's & Dementia. 2014;10(3, Supplement):S213-S25.

55. Goldman SM. Environmental Toxins and Parkinson's Disease. Annual Review of Pharmacology and Toxicology. 2014;54(Volume 54, 2014):141-64.

56. Schrag A, Bohlken J, Dammertz L, Teipel S, Hermann W, Akmatov MK, et al. Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. JAMA Neurology. 2023;80(2):161-71.

57. Weiner MW, Friedl KE, Pacifico A, Chapman JC, Jaffee MS, Little DM, et al. Military risk factors for Alzheimer's disease. Alzheimer's & Dementia. 2013;9(4):445-51.

58. Australian Institute of Health and Welfare. Head injuries in Australia 2020–21 [Internet]. Canberra: Australian Institute of Health and Welfare, 2023 [cited 2025 Apr. 1]. Available from: https://www.aihw.gov.au/reports/injury/head-injuries-in-australia-2020-21.

59. Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2022–2023 [Internet]. Canberra: Australian Institute of Health and Welfare, 2024 [cited 2025 Apr. 1]. Available from: https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey.

60. Rosas I, Morís G, Coto E, Blázquez-Estrada M, Suárez E, García-Fernández C, et al. Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism & Related Disorders. 2022;97:79-83.

61. Gabbert C, König IR, Lüth T, Kasten M, Grünewald A, Klein C, Trinh J. Lifestyle factors and clinical severity of Parkinson’s disease. Sci Rep-Uk. 2023;13(1):9537.

62. Paul KC, Chuang YH, Shih IF, Keener A, Bordelon Y, Bronstein JM, Ritz B. The association between lifestyle factors and Parkinson's disease progression and mortality. Mov Disord. 2019;34(1):58-66.

63. Menza M, Dobkin RD, Marin H, Bienfait K. Sleep disturbances in Parkinson's disease. Mov Disord. 2010;25 Suppl 1(Suppl 1):S117-22.

64. Bollu PC, Sahota P. Sleep and Parkinson Disease. Mo Med. 2017;114(5):381-6.

65. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, García-Sánchez C, Gironell A, Study TG. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Movement Disord. 2008;23(13):1889-96.

66. Aarsland D, Brønnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. Journal of Neurology, Neurosurgery & Psychiatry. 2007;78(1):36-42.

67. Han JW, Ahn YD, Kim WS, Shin CM, Jeong SJ, Song YS, et al. Psychiatric Manifestation in Patients with Parkinson's Disease. J Korean Med Sci. 2018;33(47):e300.

68. Burchill E, Watson CJ, Fanshawe JB, Badenoch JB, Rengasamy E, Ghanem DA, et al. The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. The Lancet Regional Health – Europe. 2024;39.

69. Santiago JA, Bottero V, Potashkin JA. Biological and Clinical Implications of Comorbidities in Parkinson's Disease. Front Aging Neurosci. 2017;9:394.

70. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121-34.

71. Marsh L. Neuropsychiatric Aspects of Parkinson's Disease. Psychosomatics. 2000;41(1):15-23.

72. Smeland OB, Shadrin A, Bahrami S, Broce I, Tesli M, Frei O, et al. Genome-wide Association Analysis of Parkinson's Disease and Schizophrenia Reveals Shared Genetic Architecture and Identifies Novel Risk Loci. Biological Psychiatry. 2021;89(3):227-35.

73. Leentjens AF. Parkinson disease: Depression-risk factor or early symptom in Parkinson disease? Nat Rev Neurol. 2015;11(8):432-3.

74. Scott GD, Lim MM, Drake MG, Woltjer R, Quinn JF. Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans. Movement Disord. 2021;36(9):2094-103.

75. Zhang JF, Wang XX, Feng Y, Fekete R, Jankovic J, Wu YC. Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Front Psychiatry. 2021;12:635494.

76. Weintraub D, Claassen DO. Impulse Control and Related Disorders in Parkinson's Disease. Int Rev Neurobiol. 2017;133:679-717.

77. Debove I, Paschen S, Amstutz D, Cardoso F, Corvol J-C, Fung VSC, et al. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus. Movement Disorders. 2024;39(2):235-48.

78. Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, et al. Sex Differences in Striatal Dopamine Release in Healthy Adults. Biological Psychiatry. 2006;59(10):966-74.

79. Sulzer D, Antonini A, Leta V, Nordvig A, Smeyne RJ, Goldman JE, et al. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. npj Parkinson's Disease. 2020;6(1):18.

80. Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected by COVID-19. Movement Disord. 2020;35(6):905-8.

81. Australian Institute of Health and Welfare. Immunisation and vaccination 2024 [Internet]. Canberra: Australian Institute of Health and Welfare, 2024 [cited 2025 Apr. 2]. Available from: https://www.aihw.gov.au/reports/australias-health/immunisation-and-vaccination.

82. Australian Government Department of Health and Aged Care. Priority groups for COVID-19 Vaccination Program: Phase 1b. 2021 [cited 2025 Apr. 2]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.health.gov.au/sites/default/files/documents/2021/03/priority-groups-for-covid-19-vaccination-program-phase-1b_1.pdf.

83. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal T, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043-54.

84. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-20.

85. Dennis Y, Laura IR, Luis MG-M, Victor F-O, Hugo M-B, Wai YY, et al. 3039 Monogenic Parkinson's Disease Australia (MonoPDAus) initiative: study protocol. BMJ Neurology Open. 2024;6.

86. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord. 2012;27(2):242-7.

Tables

Table 1 Overview of the questionnaire content in the APGS

Category	Included variables
Sociodemographic information	Age, sex, ethnicity, height, weight, marital status, number of children, education level, number of languages spoken, religion or spiritual affiliation, chronotype, and handedness.
Parkinson's disease-related outcomes	Age at symptom onset, lateralisation of symptom onset, side of the body affected at symptom onset, initial symptoms, age at diagnosis, specialty of the diagnosing clinician, and experiences related to PD, such as loss of smell, falls, postural dizziness, memory changes, sleep disturbances, pain, levodopa use, and PD-related procedures.
Family history	Family history of neurological disorders, such as PD, atypical parkinsonism, Alzheimer's disease, dementia, epilepsy, Huntington's disease, motor neuron disease, tremor, cerebellar ataxia, multiple system atrophy, myoclonus, and other related conditions.
Lifestyle, events, and environmental risk factors	Alcohol, coffee, tea, and other caffeinated drink consumption; well water consumption; smoking habits; second-hand smoke exposure; major head trauma; heavy metal poisoning; pesticide or herbicide exposure; and agricultural and other high-risk occupations.
Medical history	Presence of other medical conditions, as diagnosed by a clinician or specialist, including neurological, psychiatric, cardiovascular, metabolic, gastrointestinal, musculoskeletal, endocrine, skin, eye/vision, among others.
Impulsive and compulsive behaviours	Severity and frequency of compulsive behaviours (gambling, buying, eating, sexual behaviour, hobbyism, punding, and PD medication use) assessed using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease Rating Scale (QUIP-RS),[86] with four primary questions on a 5-point Likert scale.
Impact of COVID-19	Vaccination status, number of vaccinations, incidence of infection, symptom severity, and COVID-19-related hospitalisations.

Table 2 Sociodemographic characteristics in the APGS cohort (N=11,986)

	All	Female	Male	*P* value
Response type, n (%)	**11,986 (100)*			
Online questionnaire	10,667 (89.0)	3,857 (87.48)	6,798 (89.86)	<0.001
Paper questionnaire	1,319 (11.0)	552 (12.52)	767 (10.14)	
Age (year)	*11,982 (99.97)*			
Mean ± SD	70.76 ± 9.18	70.34 ± 9.32	71.01 ± 9.09	<0.001
Median [IQR]	71 [65-77]	70 [65-77]	71 [66-77]	
Sex, n (%)	*11,974 (99.9)*			
Male	7,565 (63.18)	-	-	<0.001
Female	4,409 (36.82)	-	-	
Ethnicity, n (%)	*11,922 (99.47)*			
European	11,141 (93.45)	4,099 (93.76)	7,033 (93.3)	
Mixed	202 (1.69)	63 (1.44)	137 (1.82)	
East Asian	191 (1.6)	80 (1.83)	111 (1.47)	
South Asian	130 (1.09)	40 (0.91)	90 (1.19)	
Indigenous or Torres Strait Islander	75 (0.63)	23 (0.53)	52 (0.69)	0.177
Southeast Asian	48 (0.4)	23 (0.53)	25 (0.33)	
Middle Eastern	39 (0.33)	12 (0.27)	27 (0.36)	
Latin American	34 (0.29)	11 (0.25)	23 (0.31)	
African	24 (0.2)	6 (0.14)	18 (0.24)	
Pacific Islander	21 (0.18)	10 (0.23)	11 (0.15)	
Other	17 (0.14)	5 (0.11)	12 (0.15)	
Height (cm)	*10,300 (85.93)*			
Mean ± SD	170.53 ± 10.25	161.58 ± 7.52	175.32 ± 8.07	<0.001
Median [IQR]	171 [163-178]	162 [156-166]	176 [170-180]	
Weight (kg)	*10,639 (88.76)*			
Mean ± SD	78.88 ± 17.26	69.91 ± 16.52	83.73 ± 15.62	<0.001
Median [IQR]	78 [68-89]	68 [58-80]	82 [74-92]	
BMI (kg/m^2)	*10,009 (83.51)*			
Mean ± SD	27.09 ± 5.30	26.74 ± 5.99	27.28 ± 4.89	<0.001
Median [IQR]	26.35 [23.53-29.75]	25.82 [22.35-30.12]	26.54 [24.07-29.63]	
Marital status, n (%)	*11,978 (99.93)*			
Married or de facto	9,378 (78.29)	2,966 (67.32)	6,404 (84.71)	
Separated or divorced	1,052 (8.78)	554 (12.57)	495 (6.55)	<0.001
Widowed	952 (7.95)	657 (14.91)	294 (3.89)	

Single or never married	411 (3.43)	165 (3.74)	246 (3.25)	
In a relationship but not living together	165 (1.38)	56 (1.27)	109 (1.44)	
Other	20 (0.17)	8 (0.18)	12 (0.16)	
Have children, n (%)	***11,981 (99.96)***			
Yes	10,667 (89.03)	3,920 (88.93)	6,737 (89.1)	0.794
Number of children, n (%)	***10,620 (88.6)***			
1	1,064 (10.02)	428 (10.96)	636 (9.49)	
2	4,813 (45.32)	1,768 (45.26)	3,042 (45.38)	0.06
3	3,197 (30.1)	1,169 (29.93)	2,024 (30.19)	
> 3	1,546 (14.56)	541 (13.85)	1,002 (14.95)	
Highest qualification, n (%)	***11,939 (99.61)***			
Kindergarten or never attended	11 (0.09)	2 (0.05)	9 (0.12)	
Secondary school or less	3,093 (25.91)	1,278 (29.08)	1,810 (24.03)	
Senior secondary school	1,699 (14.23)	608 (13.83)	1,091 (14.48)	
Certificate III/IV	1,304 (10.92)	434 (9.87)	869 (11.54)	<0.001
Advanced diploma or diploma	1,694 (14.19)	615 (13.99)	1,078 (14.31)	
Bachelor's degree	1,751 (14.67)	598 (13.61)	1,151 (15.28)	
Graduate diploma or certificate	1,010 (8.46)	442 (10.06)	567 (7.53)	
Postgraduate degree	1,377 (11.53)	418 (9.51)	957 (12.71)	
Speak >1 language, n (%)	***11,967 (99.84)***			
Yes	1,674 (13.99)	586 (13.31)	1,086 (14.38)	0.108
Religious or spiritual, n (%)	***11,946 (99.67)***			
Yes	4,456 (37.3)	2,022 (46.04)	2,428 (32.19)	<0.001
Chronotype, n (%)	***11,961 (99.79)***			
Morning person	6,177 (51.64)	2,269 (51.54)	3,903 (51.72)	
Evening person	2,820 (23.58)	1,179 (26.78)	1,636 (21.68)	<0.001
Neither	2,964 (24.78)	954 (21.67)	2,008 (26.61)	
Hand preference, n (%)	***11,968 (99.85)***			
Right hand	10,363 (86.59)	3,898 (88.51)	6,456 (85.49)	
Left hand	1,191 (9.95)	382 (8.67)	808 (10.7)	<0.001
Both hands	414 (3.46)	124 (2.82)	288 (3.81)	
Diet type, n (%)	***11,972 (99.88)***			
Vegetarian	322 (2.69)	162 (3.68)	159 (2.1)	
Vegan	69 (0.58)	16 (0.36)	53 (0.7)	<0.001
Other	11,581 (96.73)	4,228 (95.96)	7,342 (97.19)	

Summary statistics are presented as frequencies (n) and percentages (%) for categorical variables and as means ± standard deviations (SD) and medians [interquartile ranges (IQR)] for continuous variables,

calculated based on the available sample for each variable. *P* values were derived from independent t-tests and chi-squared tests to compare males and females for continuous and categorical variables, respectively. *The total number and percentage of participants for each variable were reported in bold and italics.

Table 3 Parkinson's disease-related outcomes in the APGS cohort (N=11,986)

	All	Female	Male	*P* value
Age of onset (year)	***11,540 (96.28)**			
Mean ± SD	63.70 ± 10.78	63.14 ± 10.82	64.03 ± 10.74	< 0.001
Median [IQR]	65 [57-71]	64 [56-71]	65 [58-72]	
Unilateral PD symptom onset, n (%)	***11,865 (98.99)***			
Yes	9,199 (77.53)	3,541 (81.2)	5,649 (75.4)	< 0.001
Symptom onset side, n (%)	***9,180 (76.59)***			
Right	4,895 (53.32)	1,832 (51.91)	3,058 (54.2)	0.034
Left	4,285 (46.68)	1,697 (48.09)	2,584 (45.8)	
First experienced symptoms, n (%)	***11,852 (98.88)***			
Tremors or shakes	6,163 (52.0)	2,303 (52.85)	3,856 (51.54)	0.175
Slowing down of movements	1,514 (12.77)	460 (10.56)	1,053 (14.07)	< 0.001
Rigidity or stiff joints	837 (7.06)	341 (7.82)	494 (6.6)	0.014
Loss of smell	700 (5.91)	260 (5.97)	440 (5.88)	0.881
Pain	224 (1.89)	94 (2.16)	129 (1.72)	0.109
Restless legs	425 (3.59)	153 (3.51)	270 (3.61)	0.822
Other	2,370 (20.0)	902 (20.7)	1,466 (19.59)	0.154
Age of diagnosis (year)	***8,229 (68.66)***			
Mean ± SD	67.38 ± 9.95	66.99 ± 10.09	67.60 ± 9.86	0.008
Median [IQR]	68 [61-75]	68 [60-74]	68 [62-75]	
Diagnosing healthcare provider, n (%)	***11,922 (99.47)***			
Neurologist	9,436 (79.15)	3,600 (82.15)	5,827 (77.4)	< 0.001
General practitioner	1,742 (14.61)	529 (12.07)	1,213 (16.11)	
Geriatrician	450 (3.77)	155 (3.54)	293 (3.89)	
Other	294 (2.47)	98 (2.24)	195 (2.59)	
PD-related symptoms				
Loss of smell, n (%)	***8,385 (69.96)***			
Yes	4,453 (53.11)	1,584 (52.75)	2,866 (53.32)	0.63
Falls, n (%)	***11,862 (98.97)***			
Yes	5,133 (43.27)	2,015 (46.23)	3,108 (41.48)	< 0.001
Postural dizziness, n (%)	***11,867 (99.01)***			
Yes	7,861 (66.24)	2,868 (65.75)	4,985 (66.52)	0.404
Changes in memory, n (%)	***8,393 (70.02)***			
Yes	5,513 (65.69)	1,852 (61.61)	3,654 (67.92)	< 0.001

#Sleep problems, n (%)	***11,857 (98.92)***			
Yes	11,442 (96.5)	4,231 (97.04)	7,200 (96.18)	0.014
Pain lasts for ≥3 months, n (%)	***8,202 (68.43)***			
Yes	4,916 (59.94)	1,907 (64.86)	3,004 (57.14)	< 0.001
Pain at enrolment, n (%)	***7,940 (66.24)***			
Yes	4,515 (56.86)	1,714 (60.06)	2,797 (55.05)	< 0.001
Levodopa use, n (%)	***11,838 (98.77)***			
Yes	11,131 (94.03)	4,069 (93.48)	7,052 (94.35)	0.057
Age at Levodopa initiation	***10,456 (87.24)***			
Mean ± SD	65.76 ± 10.21	65.43 ± 10.24	65.95 ± 10.18	0.012
Median [IQR]	67 [60-73]	66 [59-73]	67 [60-73]	
PD-related procedures, n (%)	***11,836 (98.75)***			
Yes	822 (6.94)	280 (6.43)	541 (7.24)	0.103
Procedure type, n (%)	***803 (6.7)***			
Deep brain stimulation	776 (96.64)	264 (96.7)	511 (96.6)	0.377
Duodopa	22 (2.74)	6 (2.2)	16 (3.02)	
Pallidotomy	5 (0.62)	3 (1.1)	2 (0.38)	

Summary statistics are presented as frequencies (n) and percentages (%) for categorical variables and as means ± standard deviations (SD) and medians [interquartile ranges (IQR)] for continuous variables, calculated based on the available sample for each variable. *P* values were derived from independent t-tests and chi-squared tests to compare males and females for continuous and categorical variables, respectively. PD, Parkinson's disease. *The total number and percentage of participants for each variable were reported in bold and italics. #Sleep problem is a combined measure including 'Have you ever experienced sleep problems such as difficulty in falling asleep or staying asleep during the night; difficulty staying awake during daytime activities; experiencing intense, vivid or frightening dreams; talking or moving about in your sleep as if you are ‘acting out’ a dream; or unpleasant sensation in your legs (restless legs)?'

Table 4 Lifestyle, events, and environmental risk factors in the APGS cohort (N=11,986)

	Total	Female	Male	*P* value
Caffeinated coffee consumption, n (%)	***11,713 (97.72)***			
Yes	8,857 (75.62)	3,052 (70.81)	5,799 (78.43)	< 0.001
Average number of cups per day	***8,262 (68.93)***			
Mean ± SD	2.01 ± 1.33	1.82 ± 1.21	2.10 ± 1.38	< 0.001
Median [IQR]	2 [1-3]	2 [1-2]	2 [1-3]	
Caffeinated tea consumption, n (%)	***11,700 (97.61)***			
Yes	8,182 (69.93)	3,172 (73.72)	5,004 (67.73)	< 0.001
Average number of cups per day	***7,677 (64.05)***			
Mean ± SD	2.20 ± 1.51	2.33 ± 1.51	2.12 ± 1.49	< 0.001
Median [IQR]	2 [1-3]	2 [1-3]	2 [1-3]	
Caffeinated beverage consumption, n (%)	***11,694 (97.56)***			
Yes	2,481 (21.22)	703 (16.35)	1,775 (24.04)	< 0.001
Average volume in ml per day	***1,996 (16.65)***			
Mean ± SD	291.43 ± 406.91	289.53 ± 352.77	292.28 ± 424.44	0.895
Median [IQR]	250 [100-375]	250 [78-375]	250 [100-375]	
Alcohol consumption, n (%)	***11,690 (97.53)***			
Yes	8,085 (69.16)	2,575 (59.91)	5,504 (74.55)	< 0.001
Average number of cups per week	***7,478 (62.39)***			
Mean ± SD	7.15 ± 8.57	5.20 ± 4.94	8.02 ± 9.62	< 0.001
Median [IQR]	5 [2 -10]	4 [2 -7]	6 [2 -10]	
Previous heavy alcohol use, n (%)	***10,301 (85.94)***			
Yes	3,212 (31.18)	588 (16.17)	2,622 (39.39)	< 0.001
Regular well water consumption, n (%)	***11,707 (97.67)***			
Yes	595 (5.08)	180 (4.18)	411 (5.56)	0.001
[#]Ever smoked, n (%)	***11,685 (97.49)***			
Yes	4487 (38.4)	1,393 (32.41)	3,092 (41.91)	< 0.001
Current smoker, n (%)	***4,478 (37.36)***			
Yes	254 (5.67)	81 (5.83)	173 (5.61)	0.821

Average number smoked per day	***240 (2.0)***			
Mean ± SD	12.00 ± 7.77	12.37 ± 7.62	11.82 ± 7.85	0.609
Median [IQR]	10 [5 -20]	10 [6 -16]	10 [5 -20]	
Former smoker, n (%)	***4,478 (37.36)***			
Yes	4,224 (94.33)	1,309 (94.17)	2,913 (94.39)	0.821
Average number smoked per day	***3,992 (33.31)***			
Mean ± SD	15.27 ± 11.70	12.84 ± 11.05	16.37 ± 11.82	< 0.001
Median [IQR]	15 [6 -20]	10 [5 -20]	15 [10 -20]	
Home second-hand smoke exposure, n (%)	***11,665 (97.32)***			
Yes	7,307 (62.64)	2,992 (69.69)	4,307 (58.5)	< 0.001
Workplace second-hand smoke exposure, n (%)	***11,676 (97.41)***			
Yes	2933 (25.12)	872 (20.31)	2058 (27.91)	< 0.001
Major head trauma, n (%)	***11,793 (98.39)***			
Yes	1,923 (16.31)	551 (12.7)	1,370 (18.41)	< 0.001
Major head trauma with loss of consciousness, n (%)	***1,908 (15.92)***			
Yes	1,182 (61.95)	298 (54.58)	884 (65.0)	< 0.001
Heavy metal poisoning, n (%)	***11,688 (97.51)***			
Yes	121 (1.04)	37 (0.86)	83 (1.12)	0.205
Exposure to pesticides or herbicides, n (%)	***11,748 (98.01)***			
Yes	4,306 (36.65)	1,212 (28.04)	3,090 (41.67)	< 0.001
Lived or worked on a farm for > 1 year, n (%)	***11,734 (97.9)***			
Yes	2,895 (24.67)	1,079 (24.97)	1,813 (24.49)	0.575
[$]High-risk occupation history, n (%)	***11,589 (96.69)***			
Yes	3,828 (33.03)	663 (15.57)	3,163 (43.19)	< 0.001

Summary statistics are presented as frequencies (n) and percentages (%) for categorical variables and as means ± standard deviations (SD) and medians [interquartile ranges (IQR)] for continuous variables, calculated based on the available sample for each variable. *P* values were derived from independent t-tests and chi-squared tests to compare males and females for continuous and categorical variables, respectively. *The total number and percentage of participants for each variable were reported in bold and italics. [#]Smoking variables include cigarettes, cigars or pipes. [$]High-risk occupations include

welding, metal melting, galvanisation, milling, petrochemistry, agriculture, wood processing, textile or industrial painting.

Table 5. COVID-19 related factors in the APGS cohort (N=11,986)

	All	Female	Male	*P* value
Vaccination, n (%)	***8,026 (66.96)**			
Yes	7,913 (98.59)	2,836 (98.99)	5,073 (98.39)	0.037
Vaccination dose, n (%)	***7,901 (65.92)***			
Four or more	5,865 (74.23)	2,090 (73.72)	3,772 (74.52)	
Three	1,575 (19.93)	572 (20.18)	1,003 (19.81)	0.733
Two	412 (5.21)	157 (5.54)	255 (5.04)	
One	49 (0.62)	16 (0.56)	32 (0.63)	
Positive history, n (%)	***8,007 (66.8)***			
Yes	3,515 (43.9)	1,221 (42.68)	2,292 (44.58)	0.105
Number of infections, n (%)	3,407 (28.42)			
	1.12 ± 0.37	1.13 ± 0.36	1.12 ± 0.37	0.66
Contraction timing, n (%)	***3,448 (28.77)***			
Post-vaccination	2,968 (86.08)	1,036 (86.05)	1,931 (86.13)	0.988
Pre-vaccination	480 (13.92)	168 (13.95)	311 (13.87)	
Symptom severity, n (%)	***3,494 (29.15)***			
Mild	1,958 (56.04)	666 (54.77)	1,290 (56.68)	
Moderate	1,083 (31.0)	404 (33.22)	679 (29.83)	0.02
Severe	247 (7.07)	91 (7.48)	156 (6.85)	
No symptoms at all	206 (5.9)	55 (4.52)	151 (6.63)	
Hospitalisation, n (%)	***3,492 (29.13)***			
Yes	136 (3.89)	37 (3.05)	99 (4.35)	0.072

Summary statistics are presented as frequencies (n) and percentages (%) for categorical variables and as means ± standard deviations (SD) and medians [interquartile ranges (IQR)] for continuous variables, calculated based on the available sample for each variable. *P* values were derived from independent t-tests and chi-squared tests to compare males and females for continuous and categorical variables, respectively. *The total number and percentage of participants for each variable were reported in bold and italics.

Figure legends

Figure 1. Temporal and geographic characteristics of APGS participant recruitment (May 2020–July 2024). Panel A illustrates monthly number of surveys completed by APGS participants, showing patterns of engagement over time aligned with key recruitment phases. Peaks in survey completion correspond to major study outreach events, including the pilot mail-out (June 2020), a national media campaign (April 2021), and government-assisted invitation waves in 2022, 2023, and 2024. These recruitment efforts cumulatively enabled the enrolment of 10,000 individuals with Parkinson's disease across Australia. Panel B shows the geographic composition of the APGS participants, which reflects the distribution of the Australian population.

Figure 2. Family history by sex in the APGS cohort. Panel A displays the distribution of family history for various conditions, comparing male and female participants. Bars represent the number of individuals with a positive family history, with labels indicating both the count and corresponding percentage. Statistical significance between groups is denoted as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. Panel B shows the types of blood relatives reported to have Parkinson's disease (PD). Panel C illustrates the total number of blood relatives with PD reported by each participant.

Figure 3. Comorbidities by sex in the APGS cohort. This bar chart presents the prevalence of various comorbidities, stratified by sex. Labels next to each bar show the number of affected participants, the total number who responded to each item, and the corresponding percentage. Statistical significance for differences between male and female participants is indicated as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

Figure 4. Impulsivity and compulsivity behaviours by sex in the APGS cohort. This figure compares self-reported impulsive and compulsive behaviours between female (left) and male (right) participants. The chart includes four items: (A) Frequency of intrusive thoughts or feelings of guilt related to specific behaviours; (B) Intensity of urges or desires for these behaviours, including associated distress or irritability; (C) Difficulty controlling the behaviours, such as escalation over time or inability to reduce them; (D) Engagement in actions to sustain the behaviours, including concealment, deception, debt accumulation, or illegal activities. Statistical significance is indicated for Question D: *$p < 0.01$ for eating; ***$p < 0.001$ for all other behaviours in Question D and for all behaviours in Questions A–C.

A.


Australian Parkinson's Genetics Study
Monthly surveys completed
Pilot mail-out
Media
2022 mail-out
2023 mail-out
2024 mail-out
1400
1200
1000
800
600
400
200
0
2020/05
2020/06
2020/07
2020/08
2020/09
2020/10
2020/11
2020/12
2021
2022/01
2022/02
2022/03
2022/04
2022/05
2022/06
2022/07
2022/08
2022/09
2022/10
2022/11
2022/12
2023/01
2023/02
2023/03
2023/04
2023/05
2023/06
2023/07
2023/08
2023/09
2023/10
2023/11
2023/12
2024/01
2024/02
2024/03
2024/04
2024/05
2024/06
2024/07

B.


Australian Capital Territory
2.14%
New South Wales
30.17%
Northern Territory
0.47%
Queensland
23.05%
South Australia
7.82%
Tasmania
2.82%
Victoria
24.64%
Western Australia
8.89%
0
500
1000
1500
2000
2500
3000
3500
Number of Participants


A.
Parkinson's disease
Dementia
None of the above
Alzheimer's disease
Tremor
Atypical Parkinsonism
Essential tremor
Mild cognitive impairment
Epilepsy
Vascular dementia
Frontotemporal dementia
Dementia with Lewy bodies
Motor neuron disease
Progressive supranuclear palsy
Multiple system atrophy
Dystonia
Huntington's disease
Cerebellar ataxia
Corticobasal degeneration
Myoclonus
1247 (28.28%) ***
1741 (23.01%) ***
945 (21.43%)
1594 (21.07%)
823 (18.67%) ***
1675 (22.14%) ***
676 (15.33%) *
1049 (13.87%) *
293 (6.65%)
463 (6.12%)
193 (4.38%)
337 (4.45%)
210 (4.76%) *
297 (3.93%) *
145 (3.29%)
231 (3.05%)
164 (3.72%) **
199 (2.63%) **
156 (3.54%) ***
147 (1.94%) ***
100 (2.27%)
164 (2.17%)
97 (2.2%) *
120 (1.59%) *
73 (1.66%)
119 (1.57%)
32 (0.73%)
46 (0.61%)
26 (0.59%)
46 (0.61%)
35 (0.79%) *
34 (0.45%) *
27 (0.61%)
35 (0.46%)
18 (0.41%)
25 (0.33%)
17 (0.39%)
18 (0.24%)
7 (0.16%)
11 (0.15%)
Sex
Female
Male
0
10
20
30
40
50
Percentage (%)
B.
Frequency
1108
630
541
491
475
366
Parent
Sibling
Grandparent
Uncle
Cousin
Aunt
Family relationships
C.
Frequency
2325
463
84
16
4
4
Number of affected blood relatives


Neurological and sleep disorder
Brain infection
94/4332 (2.17)
159/7431 (2.14)
Brain bleeding
77/2985 (2.58) *
193/5330 (3.62) *
Parkinson's disease dementia
123/2925 (4.21) ***
349/5224 (6.68) ***
Dementia with Lewy bodies
33/4220 (0.78) ***
165/7248 (2.28) ***
Vascular dementia
8/2906 (0.28) *
36/5205 (0.69) *
Alzheimer's disease
32/4225 (0.76) *
92/7271 (1.27) *
Mild cognitive impairment
222/4115 (5.39) ***
642/7120 (9.02) ***
Motor neuron disease
6/4220 (0.14)
7/7277 (0.1)
Essential tremor
525/4187 (12.54)
845/7213 (11.71)
Drug induced tremor
70/4215 (1.66) **
70/7243 (0.97) **
Familiar tremor
136/4183 (3.25)
205/7202 (2.85)
Multiple system atrophy
35/4193 (0.83) ***
21/7222 (0.29) ***
Progressive supranuclear palsy
25/4203 (0.59)
41/7249 (0.57)
Corticobasal degeneration
16/4213 (0.38)
18/7270 (0.25)
Multiple sclerosis
17/4022 (0.42)
14/7009 (0.2)
REM sleep behaviour disorder
303/4238 (7.15) ***
882/7295 (12.09) ***
Sleep apnea
394/4254 (9.26) ***
1392/7312 (19.04) ***
Narcolepsy
10/4001 (0.25) *
38/6997 (0.54) *
Insomnia
602/4056 (14.84) ***
608/7040 (8.64) ***
Epilepsy/seizure
39/1224 (3.19)
48/1928 (2.49)
Stroke
175/4022 (4.35) ***
452/6988 (6.47) ***
Migraine
1116/4109 (27.16) ***
971/7094 (13.69) ***
Restless leg syndrome
639/2933 (21.79) **
986/5248 (18.79) **
Autism spectrum disorder
18/4046 (0.44) *
63/7020 (0.9) *
Mental health condition
Depression
1393/4265 (32.66) ***
1909/7327 (26.05) ***
Obsessive compulsive disorder
89/4027 (2.21)
134/7018 (1.91)
Schizophrenia
46/4028 (1.14)
59/7014 (0.84)
Anxiety
929/4104 (22.64) ***
1183/7074 (16.72) ***
Attention deficit hyperactivity disorder
32/4048 (0.79)
72/7017 (1.03)
Bipolar disorder
74/4047 (1.83)
99/7026 (1.41)
Bulimia
26/3992 (0.65) **
15/6939 (0.22) **
Anorexia
47/4012 (1.17) ***
12/6966 (0.17) ***
Cardiovascular and metabolic condition
Diabetes
467/4068 (11.48) ***
1023/7036 (14.54) ***
Heart attack
134/4043 (3.31) ***
562/7001 (8.03) ***
Heart disease
304/4045 (7.52) ***
1210/7021 (17.23) ***
High blood pressure
1612/4118 (39.15) **
3010/7098 (42.41) **
High cholesterol
1432/4085 (35.06) **
2682/7075 (37.91) **
Hypotension
287/4017 (7.14) *
424/6956 (6.1) *
0 10 20 30 40 50 60 70 80
Percentage (%)
Gastrointestinal condition
Constipation
1886/4104 (45.96) ***
2602/7069 (36.81) ***
Peptic ulcer
228/3968 (5.75)
419/6949 (6.03)
Inflammatory bowel disease
249/3986 (6.25) ***
202/6950 (2.91) ***
Ulcerative colitis
75/3953 (1.9)
107/6895 (1.55)
Frequent acid reflux
1168/4054 (28.81) ***
1785/7036 (25.37) ***
Coeliac disease
90/3978 (2.26) ***
75/6936 (1.08) ***
Crohn's disease
39/3962 (0.98)
58/6902 (0.84)
Gallstones
796/4016 (19.82) ***
687/6955 (9.88) ***
Musculoskeletal condition
Osteoarthritis
1526/4010 (38.05) ***
1606/6953 (23.1) ***
Osteoporosis
992/3967 (25.01) ***
500/6872 (7.28) ***
Rheumatoid arthritis
273/3921 (6.96) ***
335/6887 (4.86) ***
Ankylosing spondylitis
76/3957 (1.92)
120/6890 (1.74)
Neck problems
367/1234 (29.74) ***
391/1933 (20.23) ***
Back problems
2072/4106 (50.46) *
3782/7135 (53.01) *
Endocrine condition
Hyperthyroidism
157/2778 (5.65) ***
70/5029 (1.39) ***
Hypothyroidism
378/4008 (9.43) ***
163/6962 (2.34) ***
Thyroid enlargement
150/2802 (5.35) ***
103/5061 (2.04) ***
Thyroid inflammation
83/2782 (2.98) ***
66/5045 (1.31) ***
Graves' disease
23/1217 (1.89) **
11/1919 (0.57) **
Skin condition
Melanoma
542/4055 (13.37) ***
1342/7051 (19.03) ***
Non-melanoma skin cancer
889/2840 (31.3) ***
1983/5117 (38.75) ***
Eczema
346/4239 (8.16) **
479/7299 (6.56) **
Severe acne
105/2691 (3.9) *
254/4833 (5.26) *
Psoriasis
232/3910 (5.93)
455/6749 (6.74)
Cold sores
1354/4092 (33.09) ***
1732/7029 (24.64) ***
Ocular and vision condition
Glaucoma
342/4196 (8.15)
599/7242 (8.27)
Age-related macular degeneration
374/4101 (9.12) ***
830/7106 (11.68) ***
Cataract
1983/4147 (47.82) ***
2980/7157 (41.64) ***
Diabetic retinopathy
30/4084 (0.73) *
88/7084 (1.24) *
Myopia
1507/4082 (36.92) ***
2265/7065 (32.06) ***
Hyperopia
1121/4072 (27.53) ***
1609/7047 (22.83) ***
Astigmatism
767/4089 (18.76) ***
1014/7070 (14.34) ***
Thick/thin cornea
62/4076 (1.52)
96/7063 (1.36)
Optic nerve shape changes
100/4082 (2.45)
155/7065 (2.19)
Keratoconus
31/4080 (0.76)
54/7063 (0.76)
Other conditions
Hearing loss
935/4077 (22.93) ***
2551/7084 (36.01) ***
Cancer of any form
790/4159 (18.99) **
1546/7157 (21.6) **
Known allergies
2540/4230 (60.05) ***
3129/7271 (43.03) ***
Lupus
57/3933 (1.45) ***
33/6889 (0.48) ***
Lymphoedema
126/4008 (3.14) ***
73/6947 (1.05) ***
Chronic fatigue
171/3959 (4.32) **
219/6905 (3.17) **
Glandular fever
405/2983 (13.58) **
613/5328 (11.51) **
Tuberculosis
44/4052 (1.09)
55/7020 (0.78)
Chronic lung disease
124/4075 (3.04)
215/7043 (3.05)
Kidney disease
117/1292 (9.06) *
248/2089 (11.87) *
Sex
Female
Male
0 10 20 30 40 50 60 70 80
Percentage (%)


(A)
Gambling
87.5%
78.8%
7.3%
12.5%
3.8%
6.1%
1.1%
2.0%
0.2%
0.6%
Sex
55.8%
23.1%
24.5%
20.5%
16.8%
34.5%
2.5%
16.9%
0.3%
5.0%
Buying
49.7%
48.4%
22.0%
27.3%
22.0%
19.4%
5.3%
4.0%
1.0%
1.0%
Eating
36.2%
35.4%
19.4%
20.0%
28.2%
27.4%
13.8%
14.8%
2.4%
2.4%
Performing tasks or hobbies
35.8%
29.0%
17.1%
19.4%
27.4%
29.6%
15.8%
18.0%
4.0%
3.9%
Repeating simple activities
47.3%
39.1%
21.0%
25.4%
22.2%
24.5%
7.7%
9.1%
1.8%
2.0%
PD medication use
41.9%
35.6%
17.7%
20.0%
18.6%
21.5%
14.9%
16.5%
7.0%
6.4%
100 75 50 25 0 25 50 75 100
Percentage (%)
(B)
Gambling
93.3%
88.0%
3.8%
7.6%
2.1%
3.0%
0.6%
1.0%
0.2%
0.5%
Sex
82.1%
49.5%
11.0%
19.6%
5.8%
21.1%
0.8%
7.4%
0.3%
2.4%
Buying
75.6%
71.1%
12.6%
18.7%
9.3%
8.4%
1.7%
1.4%
0.7%
0.4%
Eating
65.3%
60.9%
14.5%
19.5%
14.7%
14.0%
4.3%
4.7%
1.2%
0.9%
Performing tasks or hobbies
62.4%
53.9%
14.6%
19.2%
15.6%
19.0%
5.5%
6.1%
2.0%
1.8%
Repeating simple activities
65.7%
57.4%
14.7%
20.1%
14.2%
16.2%
4.2%
4.9%
1.1%
1.4%
PD medication use
69.0%
61.2%
13.7%
18.6%
10.4%
12.6%
4.3%
5.3%
2.5%
2.3%
100 75 50 25 0 25 50 75 100
Percentage (%)
(C)
Gambling
94.8%
90.2%
2.7%
5.8%
1.9%
2.8%
0.5%
0.9%
0.1%
0.4%
Sex
91.1%
65.6%
6.4%
18.1%
2.0%
11.4%
0.4%
3.7%
0.1%
1.2%
Buying
81.6%
77.9%
10.6%
15.8%
6.3%
5.4%
1.0%
0.7%
0.5%
0.3%
Eating
68.1%
65.9%
14.2%
17.3%
13.6%
12.8%
3.0%
3.3%
1.1%
0.7%
Performing tasks or hobbies
73.8%
66.0%
12.8%
18.1%
9.7%
12.1%
3.0%
3.0%
0.8%
0.8%
Repeating simple activities
75.6%
67.1%
12.6%
18.2%
8.8%
11.2%
2.4%
2.8%
0.7%
0.6%
PD medication use
79.6%
71.3%
10.8%
16.0%
6.6%
8.8%
1.6%
2.7%
1.4%
1.2%
100 75 50 25 0 25 50 75 100
Percentage (%)
(D)
Gambling
96.9%
94.0%
1.7%
3.6%
1.2%
1.6%
0.2%
0.5%
0.0%
0.3%
Sex
95.9%
80.6%
3.1%
10.2%
0.9%
6.9%
0.1%
1.7%
0.0%
0.6%
Buying
89.2%
87.2%
6.4%
8.8%
3.7%
3.3%
0.5%
0.4%
0.3%
0.3%
Eating
84.7%
82.8%
7.7%
10.0%
5.9%
5.6%
1.3%
1.2%
0.4%
0.4%
Performing tasks or hobbies
90.8%
85.5%
4.8%
8.9%
3.5%
4.4%
0.6%
0.9%
0.3%
0.3%
Repeating simple activities
90.6%
86.1%
5.1%
8.7%
3.3%
3.9%
0.8%
0.9%
0.2%
0.3%
PD medication use
92.6%
87.3%
3.9%
7.4%
2.2%
3.5%
0.5%
1.0%
0.7%
0.8%
Response
Never
Rarely
Sometimes
Often
Very Often
100 75 50 25 0 25 50 75 100
Percentage (%)